TALS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 16.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Talaris Therapeutics Insider Trading History Chart

Talaris Therapeutics Share Price & Price History

^$47.98

+0.30 (1.20%)

As of 10/28/2025 01:00 AM ET

Talaris Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2023	Suzanne Ildstad	Director	Sell	12,942	$2.49	$32,225.58	3,771,392
6/12/2023	Suzanne Ildstad	Director	Sell	16,870	$2.59	$43,693.30	3,798,542
6/9/2023	Suzanne Ildstad	Director	Sell	25,419	$2.46	$62,530.74	3,815,412
6/7/2023	Suzanne Ildstad	Director	Sell	75,001	$2.39	$179,252.39	3,881,473
6/5/2023	Suzanne Ildstad	Director	Sell	7,841	$2.52	$19,759.32	2,782,023
6/1/2023	Suzanne Ildstad	Director	Sell	15,713	$2.56	$40,225.28	2,805,682
4/21/2023	Suzanne Ildstad	Director	Sell	15,004	$2.35	$35,259.40	2,821,395
4/19/2023	Suzanne Ildstad	Director	Sell	21,753	$2.16	$46,986.48	2,883,389
4/17/2023	Suzanne Ildstad	Director	Sell	99,771	$2.14	$213,509.94	2,954,353
3/17/2023	Suzanne Ildstad	Director	Sell	10,436	$2.06	$21,498.16	3,054,124
3/1/2023	Suzanne Ildstad	Director	Sell	29	$2.05	$59.45	3,071,366
2/21/2023	Suzanne Ildstad	Director	Sell	3,500	$2.05	$7,175.00	3,071,395
2/16/2023	Suzanne Ildstad	Director	Sell	2,939	$2.06	$6,054.34	3,078,507

SEC Filings (Institutional Ownership Changes) for Talaris Therapeutics (NASDAQ:TALS)

67.61% of Talaris Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Talaris Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2023	RA Capital Management L.P.	2,403,238	$6.75M	0.1%	+3.0%	5.620%
11/15/2023	Affinity Asset Advisors LLC	400,000	$1.12M	0.3%	+100.0%	0.935%
11/7/2023	Barclays PLC	17,696	$50K	0.0%	+151.0%	0.041%
10/30/2023	Freedom Wealth Alliance LLC	16,145	$45K	0.1%	N/A	0.038%
10/27/2023	Marquette Asset Management LLC	40,028	$0.11M	0.0%	-60.5%	0.094%
10/27/2023	Acuitas Investments LLC	194,547	$0.55M	0.3%	-60.4%	0.455%
8/21/2023	Affinity Asset Advisors LLC	200,000	$0.61M	0.2%	N/A	0.476%
8/15/2023	RA Capital Management L.P.	2,333,175	$7.09M	0.1%	N/A	5.554%
8/15/2023	Corsair Capital Management L.P.	55,000	$0.17M	0.1%	N/A	0.131%
8/14/2023	Great Point Partners LLC	666,033	$2.03M	0.4%	N/A	1.585%
8/14/2023	Prelude Capital Management LLC	15,727	$48K	0.0%	N/A	0.037%
8/7/2023	Acadian Asset Management LLC	11,215	$34K	0.0%	-95.3%	0.027%
8/2/2023	Values First Advisors Inc.	32,009	$97K	0.1%	-39.5%	0.076%
8/2/2023	Bank of Montreal Can	12,698	$41K	0.0%	N/A	0.030%
7/24/2023	BML Capital Management LLC	2,000,000	$6.08M	5.5%	+3.7%	4.761%
5/11/2023	Acadian Asset Management LLC	238,513	$0.45M	0.0%	+114.1%	0.568%
5/8/2023	Bailard Inc.	14,773	$28K	0.0%	N/A	0.035%
5/1/2023	Marquette Asset Management LLC	101,375	$0.19M	0.1%	+27.7%	0.241%
4/14/2023	BML Capital Management LLC	1,929,484	$3.63M	3.1%	N/A	4.593%
2/9/2023	Chicago Partners Investment Group LLC	14,834	$26K	0.0%	N/A	0.036%
2/8/2023	Prospera Financial Services Inc	35,532	$36K	0.0%	+174.3%	0.085%
1/20/2023	Values First Advisors Inc.	39,891	$41K	0.0%	+29.9%	0.096%
1/12/2023	Marquette Asset Management LLC	79,381	$81K	0.0%	N/A	0.190%
12/2/2022	Values First Advisors Inc.	30,715	$81K	0.1%	+163.0%	0.074%
11/15/2022	Logos Global Management LP	197,913	$0.52M	0.1%	-27.0%	0.475%
11/15/2022	Caas Capital Management LP	297,707	$0.78M	0.0%	N/A	0.714%
11/14/2022	Cormorant Asset Management LP	900,649	$2.37M	0.2%	-23.3%	2.160%
11/10/2022	Bank of Montreal Can	334,061	$1.19M	0.0%	+1,388.6%	0.801%
11/3/2022	Aisling Capital Management LP	175,000	$0.46M	0.3%	-74.4%	0.420%
10/31/2022	SG Americas Securities LLC	10,403	$27K	0.0%	N/A	0.025%
10/27/2022	Prospera Financial Services Inc	12,952	$34K	0.0%	N/A	0.031%
8/15/2022	Hhlr Advisors LTD.	266,154	$1.20M	0.0%	-61.9%	0.642%
8/12/2022	Ensign Peak Advisors Inc	42,833	$0.19M	0.0%	-9.9%	0.103%
8/5/2022	State Board of Administration of Florida Retirement System	14,260	$64K	0.0%	N/A	0.034%
7/20/2022	Values First Advisors Inc.	11,677	$53K	0.0%	N/A	0.028%
6/30/2022	Amalgamated Bank	3,184	$31K	0.0%	N/A	0.008%
5/17/2022	Hhlr Advisors LTD.	698,797	$6.88M	0.1%	-8.3%	1.685%
5/10/2022	Sectoral Asset Management Inc.	228,624	$2.25M	0.4%	-12.3%	0.551%
5/10/2022	Nicholas Investment Partners LP	22,500	$0.22M	0.0%	N/A	0.054%
5/5/2022	New York State Common Retirement Fund	14,794	$0.15M	0.0%	+45.2%	0.036%
5/4/2022	Prospera Financial Services Inc	5,055	$50K	0.0%	N/A	0.012%
2/14/2022	Citadel Advisors LLC	2,661,636	$40.70M	0.0%	-0.3%	6.436%
2/11/2022	Ensign Peak Advisors Inc	47,548	$0.73M	0.0%	N/A	0.115%
2/8/2022	ProShare Advisors LLC	10,482	$0.16M	0.0%	N/A	0.025%
2/8/2022	Northern Trust Corp	168,045	$2.57M	0.0%	+102.5%	0.406%
2/2/2022	New York State Common Retirement Fund	10,189	$0.16M	0.0%	+32.5%	0.025%
1/31/2022	Altium Wealth Management LLC	59,520	$0.91M	0.1%	N/A	0.144%
11/16/2021	Citadel Advisors LLC	2,669,466	$35.41M	0.0%	0.0%	6.456%
11/15/2021	Tudor Investment Corp Et Al	97,825	$1.33M	0.0%	-1.1%	0.237%
11/15/2021	Sectoral Asset Management Inc	814,163	$11.04M	0.9%	+14.5%	1.969%
11/15/2021	Caas Capital Management LP	12,493	$0.17M	0.0%	-86.1%	0.030%
11/12/2021	Ghisallo Capital Management LLC	15,000	$0.20M	0.0%	+50.0%	0.036%
11/12/2021	Geode Capital Management LLC	171,335	$2.32M	0.0%	+11.2%	0.414%
11/10/2021	Healthcare of Ontario Pension Plan Trust Fund	76,800	$1.04M	0.0%	N/A	0.186%
11/9/2021	BlackRock Inc.	1,731,832	$23.48M	0.0%	-2.3%	4.188%

Data available starting January 2016

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

Today's Range

Now: $47.98

$47.98

50 Day Range

MA: $18.84

$12.36

$28.36

52 Week Range

Now: $47.98

$0.89

$27.95

Volume

N/A

Average Volume

386,531 shs

Market Capitalization

$2.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18